M. Kahveci Et Al. , "Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , vol.74, Lisbon, Portugal, pp.867-868, 2019
Kahveci, M. Et Al. 2019. Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety. Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (Lisbon, Portugal), 867-868.
Kahveci, M., Sahiner, U. M., Buyuktiryaki, B., Sekerel, B. E., & UYSAL SOYER, Ö., (2019). Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety . Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.867-868). Lisbon, Portugal
Kahveci, M. Et Al. "Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Lisbon, Portugal, 2019
Kahveci, M. Et Al. "Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Lisbon, Portugal, pp.867-868, 2019
Kahveci, M. Et Al. (2019) . "Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Lisbon, Portugal, pp.867-868.
@conferencepaper{conferencepaper, author={M. Kahveci Et Al. }, title={Omalizumab treatment in children with chronic spontaneous urticaria: Efficacy and safety}, congress name={Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={Lisbon}, country={Portugal}, year={2019}, pages={867-868} }